Contact us

877-469-1TRM
424-208-8866

Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients

A Multi-Center Relative Bioavailability Study of Azacitidine 75 mg/m2 Subcutaneous Injection In Myelodysplastic Syndrome Patients Under Fasting Conditions

For more information, please visit ClinicalTrials.gov

Patient Population Investigational Product(s) Phase Status
Myelodysplastic Syndrome Vidaza I Closed